A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Adrenocortical carcinoma; Bladder cancer; Carcinoma; Neuroendocrine carcinoma; Penile cancer; Prostate cancer; Squamous cell cancer; Tumours
- Focus Therapeutic Use
- 05 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 24 Oct 2023 Results (n=49) of analysis of the fully accrued BCVH cohorts presented at the 48th European Society for Medical Oncology Congress
- 05 Jul 2022 Planned primary completion date changed from 31 May 2022 to 31 Dec 2023.